SCHEMBL13488129

SCHEMBL13488129

CC1(C)c2ccccc2-c2ccc(-c3ccc4c(-c5cccnc5)c5ccccc5c(-c5ccc6c(c5)C(C)(C)c5ccccc5-6)c4c3)cc21

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK2 Q15119 6/20 0.49
CYP11B1 P15538 5/20 0.38
TDP2 O95551 2/20 0.37
CYP11B2 P19099 4/20 0.37
CYP17A1 P05093 1/20 0.37
CYP19A1 P11511 1/20 0.37
CLK4 Q9HAZ1 2/20 0.36
CHEK1 O14757 1/20 0.36
AURKA O14965 1/20 0.36
DAPK3 O43293 1/20 0.36
JAK2 O60674 1/20 0.36
PRKD3 O94806 1/20 0.36
MAP4K4 O95819 1/20 0.36
PAK4 O96013 1/20 0.36
ABL1 P00519 1/20 0.36
LCK P06239 1/20 0.36
FYN P06241 1/20 0.36
CSF1R P07333 1/20 0.36
RET P07949 1/20 0.36
IGF1R P08069 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13487899 0.98 PDK2 (0.47) PDK2CYP11B1TDP2CYP11B2CYP17A1
SCHEMBL13487757 0.97 PDK2 (0.46) PDK2CYP11B1TDP2CYP11B2CYP17A1
SCHEMBL15977617 0.96 PDK2 (0.51) PDK2CYP11B1TDP2CYP11B2CYP17A1
SCHEMBL13488052 0.94 CYP11B2 (0.49) PDK2CYP11B1CYP11B2CYP17A1CYP19A1
SCHEMBL13487357 0.92 PDK2 (0.45) PDK2CYP11B1TDP2CYP11B2CYP17A1
SCHEMBL13487838 0.92 PDK2 (0.44) PDK2CYP11B1CYP17A1CYP3A4LMNA
SCHEMBL13487981 0.91 PDK2 (0.42) PDK2CYP11B1CYP11B2CYP17A1CYP19A1
SCHEMBL15977514 0.91 PDK2 (0.47) PDK2CYP11B1TDP2CYP11B2CYP17A1
SCHEMBL10153148 0.91 PDK2 (0.47) PDK2CYP11B1TDP2CYP11B2CYP17A1
SCHEMBL13487512 0.91 PDK2 (0.42) PDK2CYP11B1TDP2CYP11B2CYP17A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100045170-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-25 US disclosed
US-20100045170-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-25 US disclosed
EP-2108689-A2 Novel organic electroluminescent compounds and organic electroluminescent device using the same Gracel Display Inc. (KR) 2009-10-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100045170-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same OCIAD1, OCIAD2, ORMDL3 PDK2 1456/4885CYP11B1 492/4885TDP2 2332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.